EMA recommends Rezurock (belumosudil) for chronic graft-versus-host disease, with the drug. Meetings unmet needs via ...
Hosted on MSN
What To Know About Graft vs. Host Disease (GVHD)
Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens when ...
Equillium, Inc. (NASDAQ:EQ) released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host ...
SEATTLE — March 5, 2025 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. March is the awareness month for colorectal cancer and multiple ...
Hematopoietic cell transplantation (HCT), also known as bone marrow transplantation, is a critical treatment for blood cancers such as leukemia, lymphoma, and myeloma, as well as certain genetic and ...
Refined response (RR) criteria for acute graft-vs-host disease (GVHD) showed improved predictive performance over conventional criteria, with higher area under the curve (AUC) values and negative ...
MiNK Therapeutics receives an NIAID grant to develop iNKT cell therapies for preventing graft-versus-host disease in stem cell transplants. MiNK Therapeutics, Inc., a biopharmaceutical company ...
A research team has identified the impact of stem cell infusion timing on the incidence and severity of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation ...
Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after ...
Hematopoietic stem cell transplantation (HSCT) remains a vital treatment for a variety of haematologic malignancies and non‐malignant disorders. The procedure, involving the transfer of multipotent ...
Overall survival in hematopoietic stem cell transplant patients with hematologic malignancies: Accounting for the unobserved risk factors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results